FDA
-
-
-
-
-
-
-
Mizuho Securities Reiterates Buy Rating on Xencor (XNCR), Sees Multiple Opportunities
-
-
-
-
-
-
-
Merck (MRK) Included in Mizuho's List of Top Oncology Picks for 2021
-
-
-
-
-
-
-
Xencor Reports Fourth Quarter and Full Year 2019 Financial Results
-
-
-
-
-
-
-
Xencor Reports Fourth Quarter and Full Year 2018 Financial Results
-
-
-
-
-
-
-
Pre-Open Movers 03/21: (PRTA) (PTI) (TEUM) (GIS) (LUV) (JWN) (SRPT)
-
-
-
-
-
-
-
Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease
-
-
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

